Salute e Benessere

Global Pharmaceutical Excipients Market to Register Growth at a CAGR of ~6% by…

Key Takeaways from the Pharmaceutical Excipients Market Report Key Takeaways from the Pharmaceutical Excipients Market Report To read more about the latest highlights related to the pharmaceutical excipients market, get a snapshot of the key highlights entailed in the Global Pharmaceutical Excipients Market Report Pharmaceutical Excipients Overview Pharmaceutical excipients are non-active ingredients used in drug formulations to aid the production, stability, and effectiveness...
PR Newswire
09/09/2024

Idiopathic Pulmonary Fibrosis Treatment Drug Market to Increase 2 Folds by 2034…

Although the cause of IPF is unknown, researchers postulate that the disease probably results from genetic and environmental factors. There is a strong possibility that genetic changes increase a person's risk of developing IPF and subsequent exposure to certain environmental factors that further trigger the disease. However, much is still unknown about this emerging field of study. Although the cause of IPF is unknown, researchers postulate that the disease probably results from genetic and...
PR Newswire
09/09/2024

PATH Appoints Dr Bilal Mateen as Inaugural Chief AI Officer

Dr. Mateen is a physician by training with an academic background in health-related applications of data science and machine learning. Prior to joining PATH, he served as the Clinical Technology Lead and Senior Manager for Digital Technology at the Wellcome Trust, one of the world's largest philanthropic foundations supporting science and health research. Dr. Mateen is a physician by training with an academic background in health-related applications of data science and machine learning...
PR Newswire
09/09/2024

Microfluidic Chips Market Size to Grow USD 8770.5 Million by 2030 with a CAGR of…

Get Free Sample @ https://reports.valuates.com/request/sample/QYRE-Auto-12L12225/Global_Microfluidic_Chips_Market Get Free Sample @ https://reports.valuates.com/request/sample/QYRE-Auto-12L12225/Global_Microfluidic_Chips_Market Major Factors Driving the Growth of Microfluidic Chips Market: Due to the growing importance of microfluidic chips in a variety of applications, including drug research, environmental monitoring, and medical diagnostics, the market for these chips is...
PR Newswire
09/09/2024

Boehringer's zongertinib shows encouraging efficacy and tolerability profile in…

Beamion LUNG-1, Phase Ib met its primary endpoint, demonstrating a meaningful objective response rate (ORR) of 66.7%, as assessed by blinded independent central review (BICR) 1Preliminary activity in patients with brain metastases were also observed, with an intracranial response of 33% and 74% disease control rate (DCR) Zongertinib was generally well tolerated, with mostly mild and manageable treatment related adverse events (TRAE) and low discontinuation rate due to toxicity (3%)...
Nasdaq GlobeNewswire
09/09/2024

Seegene Expands mpox RUO Product Lineups with Enhanced Detection Assays for…

The assay meets the preferred target product profiles (TPPs) issued by the WHO, which guide manufacturers, suppliers, and researchers developing new assays for detection of viruses causing mpox. Additionally, it aligns with the preferred target analyte criteria for distinguishing between Clade I and II. The assay meets the preferred target product profiles (TPPs) issued by the WHO, which guide manufacturers, suppliers, and researchers developing new assays for detection of viruses causing…
PR Newswire
09/09/2024

Zealand Pharma announces positive topline results from 13-week Phase 1b multiple…

Company announcement – No. 44 / 2024 Zealand Pharma announces positive topline results from 13-week Phase 1b multiple ascending dose clinical trial with GLP-1/GLP-2 receptor dual agonist dapiglutidePlacebo-adjusted reductions in body weight of up to a mean of 8.3% with dapiglutide after 13 weekly dosesDapiglutide treatment with doses up to 13 mg was assessed to be safe and well-tolerated with gastrointestinal adverse events consistent with the profile reported with other incretin-based...
Nasdaq GlobeNewswire
09/09/2024

Global Automated Bioreactor Sampling Market is projected to grow at a CAGR of…

Key players in this market, are leading the innovation with advanced sampling solutions that integrate seamlessly into existing bioprocess workflows. These companies, are focusing on developing single-use and reusable systems that cater to different scales of production, from laboratory research to large-scale manufacturing. The introduction of more sophisticated analyzers, real-time monitoring capabilities, and integration with bioprocess control software is further enhancing the efficiency and…
PR Newswire
09/09/2024

Cardiac Tissue Engineering Market to Reach USD 1,333.6 M by 2029, Driven by Stem…

Browse in-depth TOC on "Cardiac Tissue Engineering Market" Browse in-depth TOC on "Cardiac Tissue Engineering Market" 426 - Tables 54 - Figures 336 - Pages Material Segmentation The market is divided into stem cells and scaffolds, with scaffolds further categorized into biological and synthetic types. In 2023, biological scaffolds held a significant market share due to their superior biological activity, which enhances cell adhesion and growth, and their ability to...
PR Newswire
09/09/2024

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 9 September 2024– On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under…
Nasdaq GlobeNewswire
09/09/2024

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S – Share repurchase programme Bagsværd, Denmark, 9 September 2024– On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a…
Nasdaq GlobeNewswire
09/09/2024

Evaxion reports 69% Overall Response Rate in its phase 2 trial on lead cancer…

Topline data from a one-year interim analysis of the ongoing phase 2 trial show that 11 out of 16 patients had objective clinical responses, equaling a 69% Overall Response Rate 15 out of the 16 patients had reduction of their tumors (target lesions)The complete one-year dataset will be presented at the ESMO congress this week and discussed at a webinar with key opinion leaderProfessor Georgina V. Long on September 18, 2024 COPENHAGEN, Denmark, Sept.09, 2024(GLOBE NEWSWIRE)...
Nasdaq GlobeNewswire
09/09/2024

Aurora Cannabis and Vectura Fertin Pharma, Inc. announce launch of novel Luo CBD…

Launch represents Vectura Fertin Pharma's first medical cannabis CBD lozenge to be introduced in Canada Launch follows announcement of commercial collaboration between Cogent International, a Vectura Fertin Pharma subsidiary, and Aurora to leverage Aurora's Canadian medical cannabis patient platformCollaboration will explore the potential to launch Vectura Fertin Pharma's future medical cannabis portfolio in CanadaEdmonton, AB, and Stamford, CT – September 9, 2024- Aurora Cannabis Inc...
Nasdaq GlobeNewswire
09/09/2024

Chiesi Global Rare Diseases Launches New Research Grant Initiative to Support…

All applications will be independently reviewed and assessed by a Steering Committee of leading experts in the lysosomal storage disorders field, who have been identified, contracted and funded by Chiesi, with the successful applicants announced in Q1 2025. All applications will be independently reviewed and assessed by a Steering Committee of leading experts in the lysosomal storage disorders field, who have been identified, contracted and funded by Chiesi, with the successful applicants...
PR Newswire
09/09/2024

Tilray Medical Supports Scientific Study on Fibromyalgia With Positive Outcomes…

Tilray Medicaltitled, Treatment in Pain Management and Other Fibromyalgia-Associated Symptoms: A Case Series (TOMAS) . The study examines the real-world impact of cannabinoid treatments on patients with fibromyalgia (FM) under the guidance of healthcare providers. The TOMAS study, consisting of patients with an average age of 52 years, examined the effects of Tilray Dried Flower THC18 on chronic pain and other FM-associated symptoms. The study sheds light on the impact of...
Nasdaq GlobeNewswire
09/09/2024

MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday…

MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11ZUG, Switzerland,September 9, 2024 – MoonLake Immunotherapeutics AG (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, will host a Capital Markets Update for investors and analysts live from New York on Wednesday, September 11 from2024, from 9:00 – 10:30 EST/06:00 – 08:30 PST/14:00 – 16:30 CETThe event will...
Nasdaq GlobeNewswire
09/09/2024

Evaxion obtains pre-clinical Proof-of-Concept for mRNA Gonorrhea vaccine…

New pre-clinical data demonstrates that the novel EVX-B2 mRNA vaccine candidate triggers a targeted immune response The specific immune response leads to the elimination of the gonorrhea bacteriaThe data confirm that Evaxion's AI-Immunology™ platform is delivery modality agnostic COPENHAGEN, Denmark, Sept.09, 2024(GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines,...
Nasdaq GlobeNewswire
09/09/2024

Tineco's FLOOR ONE STRETCH S6 Receives Floor Cleaning Solutions Gold Award

Self-cleaning and flash drying by a press of the button The integrated FlashDry self-cleaning system ensures completely autonomous cleaning and drying of the brush roll and the entire vacuum cleaner at the push of a button. During self-cleaning, dirt particles are effectively removed from the brush roll and the pipeline by a heat flow of 70℃. During this process, the bi-directional brush rotates continuously to ensure a deeper and more thorough cleaning. This means the brush becomes particularly…
PR Newswire
09/09/2024

Buyback of Class B shares in Essity during week 36, 2024

The share repurchase is financed using cash flow from current operations after the ordinary dividend with the ambition to continue with share buybacks over time as a recurring part of Essity's capital allocation. The share repurchase is financed using cash flow from current operations after the ordinary dividend with the ambition to continue with share buybacks over time as a recurring part of Essity's capital allocation. Class B shares in Essity were repurchased as follows: All purchases...
PR Newswire
09/09/2024

U-Ploid Announces Breakthrough Technology to Overcome Age-Related Infertility

"Our team is developing technology that directly targets the root cause of age-related female infertility," said Dr Chloe Charalambous, Co-founder & COO of U-Ploid Biotechnologies. "By improving the health of older eggs, we have the opportunity to help millions of people in their fertility journey." "Our team is developing technology that directly targets the root cause of age-related female infertility," said DrChloe Charalambous, Co-founder & COO of…
PR Newswire
09/09/2024

New bond financing agreement in a minimum amount of €3 million in anticipation…

Disclaimer: SAFE SA (the “Company”) has arranged financing in the form of convertible bonds into new or existing shares (OCEANE) with Global Corporate Finance Opportunities 20 (“GCFO 20”), which, after receiving the shares resulting from the conversion of these bonds, is not intended to remain a shareholder of the Company.The shares resulting from the conversion of these bonds will generally be sold on the market at very short notice, which may create strong downward pressure on the...
Nasdaq GlobeNewswire
09/09/2024

Trampoline Market to Reach $1.5 billion, Globally, by 2035 at 4.6% CAGR: Allied…

Prime determinants of growth Prime determinants of growth The trampoline market is expanding due to several important factors. The growing popularity of trampolines as an enjoyable form of physical exercise is a result of people's increased awareness of health and fitness, especially among children and adolescents. The popularity of trampoline parks along with the growth in sports and leisure activities has further stimulated market expansion. Trampolines have also become more...
PR Newswire
09/09/2024

Diamyd Medical to pursue accelerated approval pathway for Type 1 Diabetes…

Diamyd Medical recently announced Fast track designation in the U.S. for Diamyd®, and that the U.S. Food and Drug Administration (FDA) has acknowledged that accelerated approval could be sought based on a demonstration of significant treatment-related benefits on C-peptide levels, a measure of endogenous insulin production, in response to Diamyd® administration. The FDA's Accelerated approval program allows drugs for serious conditions that fills an unmet medical need to be approved based on a…
PR Newswire
09/09/2024

A. Menarini Diagnostics and Nucleix announce a strategic partnership for a…

This non-invasive CE-marked test detects primary or recurrent bladder cancer and upper tract urinary cancer. Bladder EpiCheck is included in the European Association of Urology (EAU) Clinical Guidelines as a urine test that might be used in the initial diagnostic workup of bladder cancer to avoid / implement cystoscopy and in follow-up to monitor for non-muscle invasive bladder cancer (NMIBC) tumor recurrence to replace or postpone cystoscopy. The test is also included in the EAU Clinical…
PR Newswire
09/09/2024
Altri  Comunicati